Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
Clinical trial NCT03269695 · TERMINATED
Trial details
- NCT number
- NCT03269695
- Sponsor
- Pfizer
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-20
- Primary completion
- 2021-01-07
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.